This article is more than 5 years old. Information may no longer be current.
FDA approves combination HIV treatment
Click Here to Manage Email Alerts
The FDA today approved a combination treatment for HIV-1 infection, according to a press release.
The fixed-dose combination product, to be marketed as Triumeq (ViiV Healthcare), is a combination of dolutegravir, an integrase strand transfer inhibitor, and abacavir sulfate and lamivudine, both nucleoside analogue reverse transcriptase inhibitors. The recommended dosage regimen of Triumeq in adults is one tablet daily taken orally, with or without food.
Triumeq alone is not recommended for use in patients with current or prior history of resistance to any of the three components. Triumeq alone is also not recommended for patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance, because the dose of dolutegravir in Triumeq is insufficient for these subpopulations, according to the FDA.
Triumeq is contraindicated in several subsets of patients. See the FDA site for more information.